DCOY vs DMAC

Decoy Therapeutics Inc. vs DiaMedica Therapeutics Inc. — Valuation Comparison 2026

DCOY

Biotechnology
Decoy Therapeutics Inc.
Quality
3.7
out of 10
Value Trap
39
LOW
Price
$7.91
Last close
Models
8/13
Active
VS

DMAC

Biotechnology
DiaMedica Therapeutics Inc.
Quality
4.7
out of 10
Value Trap
18
SAFE
Price
$6.16
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DCOY Fair ValueDCOY Upside DMAC Fair ValueDMAC Upside
Bayesian DCF Intrinsic $10.17 +28.5% $1.70 -72.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.72 -87.8% $0.45 -92.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DCOY vs DMAC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DCOY vs DMAC — Which Stock Is More Undervalued?

DMAC scores higher with a 4.7/10 quality rating vs DCOY's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Decoy Therapeutics Inc. (DCOY) and DiaMedica Therapeutics Inc. (DMAC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DCOY currently trades at $7.91 with a QOC of 3.7/10, while DMAC trades at $6.16 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).